Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels
Haematologica. 2021 Dec 1;106(12):3249-3252.
doi: 10.3324/haematol.2021.279509.
1 University of Namur, Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, Namur, Belgium; QUALIblood s.a., Namur. jonathan.douxfils@unamur.be.
2 University of Tours, EA7501 GICC, CHRU de Tours, Department of Haemostasis, Tours.
3 Département de Médecine, Hôpitaux Universitaires de Genève, service d'angiologie et d'hémostase et Faculté de Médecine, Geneva Platelet Group (GpG), Université de Genève, Geneva.
4 University of Namur, Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, Namur, Belgium; Clinique Saint-Luc Bouge, Department of Laboratory Medicine, Bouge.
5 Service de gériatrie, CHU UCL Namur site Sainte-Elisabeth, Namur.
6 Université Catholique de Louvain, service de gériatrie, CHU UCL Namur site Sainte-Elisabeth, Namur.
7 CHU UCL Namur | site Sainte-Elizabeth, Université catholique de Louvain, Department of Hematology, Namur Research Institute for Life Sciences, Namur Thrombosis and Hemostasis Center, Yvoir.
8 University of Namur, Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, Namur.
9 Université catholique de Louvain, CHU UCL Namur, Namur Thrombosis and Hemostasis Center, Hematology Laboratory, Namur Research Institute for Life Sciences, Yvoir.